(Update: On December 15, 2021 KEI hosted a press briefing regarding the Xtandi march-in request. Video and details available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) On November 18, 2021, Robert Sachs and Clare Love submitted a petition to the Secretary of Health and Human… Continue Reading
On November 5, 2020, Regeneron Pharmaceuticals published a redacted version of the contract awarding the company $450 million taxpayers’ dollars for the large-scale manufacture of Regeneron’s investigational COVID-19 antibody treatment. The contract uses Other Transactions Authority to weaken the U.S.… Continue Reading
Moderna has attached three COVID-19 related contracts as exhibits to its SEC 10-Q form for the quarterly period ending in October 2020. The first is the contract between the Department of Health and Human Services (HHS) and Moderna for the… Continue Reading
On April 6, 2020, KEI received a response from the National Institutes of Health (NIH) to a letter we sent to DHHS Secretary Alex Azar on March 13, 2020 regarding three areas in Section 202 of the Bayh-Dole Act that… Continue Reading
For more on KEI’s work on COVID-19, see keionline.org/coronavirus. On March 23, 2020, Knowledge Ecology International (KEI) sent a letter to Speaker Nancy Pelosi regarding a provision in the current draft of the Senate version of the coronavirus funding bill… Continue Reading
At today’s House Oversight Hearing on PrEP, one of issues will be access to Truvada (FTC+TDF), but also Descovy (FEMTRICITABINE+TENOFOVIR ALAFENAMIDE), a two drug combination, that uses TAF instead of TDF, and is less toxic than Truvada. The Goodrx price… Continue Reading
On Monday May 6, 2019, KEI gave the following intervention during the Department of Health and Human Services (HHS) Listening Session in advance of the Seventy-second World Health Assembly to be held in Geneva on May 20-28, 2019. KEI Statement… Continue Reading
On Monday May 6, 2019, KEI gave the following intervention during the Department of Health and Human Services (HHS) Listening Session in advance of the Seventy-second World Health Assembly to be held in Geneva on May 20-28, 2019. KEI Statement… Continue Reading
On April 30, 2019, KEI issued a memorandum to Congress concerning recent proposed measures to cap drug price increases and to increase the transparency of pharmaceutical research and development costs. Congress is currently considering several bills that touch on these… Continue Reading
Attached is a letter sent on September 14, 2017 to Andrew Bremberg, an Assistant to the President and the Director of the Domestic Policy Council at the White House, and Keagan Lenihan, a Senior Adviser to HHS Secretary Tom Price, regarding Zinbrytra (INN: daclizumab), a drug to approved by the FDA to treat multiple sclerosis. (PDF version here)